MakeMyTrip Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? MakeMyTrip Ltd trades at $60.56 (market cap $5.78B), while Regeneron Pharmaceuticals Inc trades at $796.95 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 14.2× MakeMyTrip Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| MMYT | REGN | |
|---|---|---|
Market Cap | $5.78B | $82.06B |
Sector | Technology | Health |
52-Week High | $103.21 | $812.27 |
52-Week Low | $36.30 | $555.51 |
Enterprise Value | $6.44B | $76.77B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $60.31, down 0.99% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth to $978M in 2025 and consistent earnings beats, though Q2 2026 missed expectations. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target. Recent news highlights travel industry momentum despite temporary air-ticketing softness.
Investment outlook appears favorable with strong fundamentals and bullish analyst consensus, though risks include rising debt levels and geopolitical travel disruptions. The stock's high P/E ratio of 267 requires sustained earnings growth to justify valuation. Recent institutional selling by Boston Common Asset Management warrants monitoring for broader sentiment shifts.
Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.
Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.
Trailing returns across standard periods
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →